Workstream Type: Policy Solutions
-
Abandon Biosimilars as Biologics are Natural Monopolies
Read More
-
List Price, Net Price, and the Rebate Caught in the Middle
Read More
-
Overview of Original Subscription Model and Features of LA and WA Proposals
Read More
-
The “Netflix Model” of Financing Hepatitis C Treatment
Read More
-
Perspective on National Coverage Analysis of CAR-T Therapies
Read More
-
The U.S. Government Should Buy Gilead for $156Bn to Save Money on Hep C
Read More
-
Part B Payment for Medicare Drugs
Read More
-
The Just Price of Cancer Drugs
Read More
-
Reforming the Payment System for Medical Oncology
Read More
-
Comparative Effectiveness Research in Medicare Coverage and Reimbursement
Read More